Article Type
Changed
Tue, 12/13/2016 - 10:27
Display Headline
We Must Lead on BEST-CLI Trial, Enroll Patients: Dr. Conte

Dr. Michael Conte issued an urgent call Thursday for vascular surgeons to enroll patients in the BEST-CLI Trial, designed to answer this question: What’s the best treatment for advanced critical limb ischemia?

“This is a key opportunity to define optimal care for patients with critical limb-threatening ischemia,” said Dr. Conte to the audience at the E. Stanley Crawford Critical Issues Forum. “Vascular surgeons are the dominant providers, and we must be the leaders.”

Dr. Michael S. Conte

Investigators hope to enroll 2,100 patients; to date the trial is at “barely one-third of that enrollment,” he said.

The National Institutes of Health is closely monitoring the trial, officially the “Best Endovascular vs. Best Surgical Therapy in Patients with Critical Limb Ischemia” trial, he said, adding, “and we must execute on this important opportunity.

“Most importantly, the trial will help us define an evidenced-based standard of care. Vascular surgeons must play a leading role in this landmark trial,” he said.

To participate and learn more, visit: www.bestcli.com.

References

Author and Disclosure Information

Publications
Sections
Author and Disclosure Information

Author and Disclosure Information

Dr. Michael Conte issued an urgent call Thursday for vascular surgeons to enroll patients in the BEST-CLI Trial, designed to answer this question: What’s the best treatment for advanced critical limb ischemia?

“This is a key opportunity to define optimal care for patients with critical limb-threatening ischemia,” said Dr. Conte to the audience at the E. Stanley Crawford Critical Issues Forum. “Vascular surgeons are the dominant providers, and we must be the leaders.”

Dr. Michael S. Conte

Investigators hope to enroll 2,100 patients; to date the trial is at “barely one-third of that enrollment,” he said.

The National Institutes of Health is closely monitoring the trial, officially the “Best Endovascular vs. Best Surgical Therapy in Patients with Critical Limb Ischemia” trial, he said, adding, “and we must execute on this important opportunity.

“Most importantly, the trial will help us define an evidenced-based standard of care. Vascular surgeons must play a leading role in this landmark trial,” he said.

To participate and learn more, visit: www.bestcli.com.

Dr. Michael Conte issued an urgent call Thursday for vascular surgeons to enroll patients in the BEST-CLI Trial, designed to answer this question: What’s the best treatment for advanced critical limb ischemia?

“This is a key opportunity to define optimal care for patients with critical limb-threatening ischemia,” said Dr. Conte to the audience at the E. Stanley Crawford Critical Issues Forum. “Vascular surgeons are the dominant providers, and we must be the leaders.”

Dr. Michael S. Conte

Investigators hope to enroll 2,100 patients; to date the trial is at “barely one-third of that enrollment,” he said.

The National Institutes of Health is closely monitoring the trial, officially the “Best Endovascular vs. Best Surgical Therapy in Patients with Critical Limb Ischemia” trial, he said, adding, “and we must execute on this important opportunity.

“Most importantly, the trial will help us define an evidenced-based standard of care. Vascular surgeons must play a leading role in this landmark trial,” he said.

To participate and learn more, visit: www.bestcli.com.

References

References

Publications
Publications
Article Type
Display Headline
We Must Lead on BEST-CLI Trial, Enroll Patients: Dr. Conte
Display Headline
We Must Lead on BEST-CLI Trial, Enroll Patients: Dr. Conte
Sections
Article Source

PURLs Copyright

Inside the Article